Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
RESORCE
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
2 other identifiers
interventional
573
20 countries
144
Brief Summary
The objective of this study was to evaluate efficacy and safety of regorafenib in patients with advanced liver cancer who had progressed after sorafenib treatment. Patients were treated with regorafenib or placebo using a 2:1 randomization scheme.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started May 2013
Longer than P75 for phase_3
144 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 21, 2013
CompletedFirst Posted
Study publicly available on registry
January 24, 2013
CompletedStudy Start
First participant enrolled
May 14, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 29, 2016
CompletedResults Posted
Study results publicly available
June 5, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
July 5, 2019
CompletedAugust 20, 2020
August 1, 2020
2.8 years
January 21, 2013
February 9, 2017
August 11, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Overall Survival (OS)
Overall Survival (OS) was defined as the time from date of randomization (Day 1) to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact.
From randomization (Day 1) of the first subject until 419 days later
Secondary Outcomes (4)
Time to Progression (TTP)
From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks) (approximately 33 months)
Progression Free Survival (PFS)
From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks)
Objective Tumor Response Rate (ORR)
From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks) (approximately 33 months)
Disease Control Rate (DCR)
From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks) (approximately 33 months)
Other Outcomes (1)
Overall Survival (OS)
From randomization (Day 1) of the first subject to end of follow upto 1710 days
Study Arms (2)
Regorafenib
EXPERIMENTAL160 mg orally (p.o.) every day (qd) for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off) plus BSC (Best Supportive Care)
Placebo
PLACEBO COMPARATOR4 matching placebo tablets for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off) plus BSC
Interventions
Eligibility Criteria
You may qualify if:
- Histological or cytological confirmation of HCC (hepatocellular carcinoma) or non-invasive diagnosis of HCC as per American Association for the Study of Liver Diseases criteria in patients with a confirmed diagnosis of cirrhosis
- Barcelona Clinic Liver Cancer stage Category B or C that cannot benefit from treatments of established efficacy with higher priority such as resection, local ablation, chemoembolization or systemic sorafenib.
- Failure to prior treatment with sorafenib (defined as documented radiological progression according to the radiology charter). Randomization needs to be performed within 10 weeks after the last treatment with sorafenib.
- Tolerability of prior treatment with sorafenib defined as not less than 20 days at a minimum daily dose of 400 mg QD within the last 28 days prior to withdrawal.
- Liver function status Child-Pugh Class A. Child Pugh status should be calculated based on clinical findings and laboratory results during the screening period.
- Local or loco-regional therapy of intrahepatic tumor lesions (e.g. surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) must have been completed \>/=4 weeks before first dose of study medication. Note: patients who received sole intrahepatic intraarterial chemotherapy, without lipiodol or embolizing agents are not eligible.
- Eastern Cooperative Oncology Group Performance Status of 0 or 1.
- Adequate bone marrow, liver and renal function as assessed by the following laboratory tests conducted within 7 days before randomization.
- Glomerular filtration rate \>/= 30 ml/min/1.73 m\^2 according to the Modification of diet in renal disease study equation.
- At least one uni-dimensional measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to RECIST (RECIST version 1.1), and modified RECIST for HCC. Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, may be considered measurable if there has been demonstrated progression in the lesion.
- Life expectancy of at least 3 months.
- Women of childbearing potential and men must agree to use adequate contraception .
You may not qualify if:
- Sorafenib treatment within 2 weeks of randomization.
- Prior systemic treatment for HCC, except sorafenib.
- Permanent discontinuation of prior sorafenib therapy due to sorafenib related toxicity.
- Known history or symptomatic metastatic brain or meningeal tumors (head CT or MRI at screening to confirm the absence of central nervous system \[CNS\] disease if patient has symptoms suggestive or consistent with CNS disease).
- Uncontrolled hypertension (systolic blood pressure \[BP\] \> 150 mmHg or diastolic pressure \> 90 mmHg despite optimal medical management).
- Uncontrolled ascites (defined as not easily controlled with diuretic or paracentesis treatment).
- Ongoing infection \> Grade 2 according to NCI-CTCAE (National Cancer Institute - Common Terminology Criteria for Adverse Events) v. 4.0. Hepatitis B is allowed if no active replication is present. Hepatitis C is allowed if no antiviral treatment is required.
- Clinically significant bleeding NCI-CTCAE version 4.0 Grade 3 or higher within 30 days before randomization.
- Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months before the start of study medication.
- Patients unable to swallow oral medications.
- Interstitial lung disease with ongoing signs and symptoms at the time of screening.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Bayerlead
Study Sites (147)
Unknown Facility
Los Angeles, California, 90048, United States
Unknown Facility
Los Angeles, California, 90095, United States
Unknown Facility
Orange, California, 92868-3201, United States
Unknown Facility
Aurora, Colorado, 80045, United States
Unknown Facility
Washington D.C., District of Columbia, 20007-2197, United States
Unknown Facility
Gainesville, Florida, 32610-0286, United States
Unknown Facility
Tampa, Florida, 33606, United States
Unknown Facility
Chicago, Illinois, 60637, United States
Unknown Facility
Louisville, Kentucky, 40202, United States
Unknown Facility
Worcester, Massachusetts, 01655, United States
Unknown Facility
Minneapolis, Minnesota, 55455, United States
Unknown Facility
St Louis, Missouri, 63110, United States
Unknown Facility
New York, New York, 10029, United States
Unknown Facility
Rochester, New York, 14642, United States
Unknown Facility
Pittsburgh, Pennsylvania, 15232, United States
Unknown Facility
Richmond, Virginia, 23249, United States
Unknown Facility
Seattle, Washington, 98101, United States
Unknown Facility
Pilar, Buenos Aires, B1629ODT, Argentina
Unknown Facility
Camperdown, New South Wales, 2050, Australia
Unknown Facility
Liverpool, New South Wales, 2170, Australia
Unknown Facility
Herston, Queensland, 4029, Australia
Unknown Facility
Clayton, Victoria, 3168, Australia
Unknown Facility
Box Hill, 3128, Australia
Unknown Facility
Graz, Styria, 8036, Austria
Unknown Facility
Linz, Upper Austria, 4020, Austria
Unknown Facility
Vienna, 1090, Austria
Unknown Facility
Bruxelles - Brussel, 1090, Belgium
Unknown Facility
La Louvière, 7100, Belgium
Unknown Facility
Salvador, Estado de Bahia, 41950-610, Brazil
Unknown Facility
São Paulo, 05403-000, Brazil
Unknown Facility
Hefei, Anhui, 230022, China
Unknown Facility
Fuzhou, Fujian, 350025, China
Unknown Facility
Guangzhou, Guangdong, 510060, China
Unknown Facility
Guangzhou, Guangdong, 510080, China
Unknown Facility
Guangzhou, Guangdong, 510515, China
Unknown Facility
Nanning, Guangxi, 530021, China
Unknown Facility
Harbin, Heilongjiang, 150081, China
Unknown Facility
Wuhan, Hubei, 430030, China
Unknown Facility
Changsha, Hunan, 410013, China
Unknown Facility
Nanjing, Jiangsu, 210002, China
Unknown Facility
Suzhou, Jiangsu, 215006, China
Unknown Facility
Dalian, Liaoning, 116011, China
Unknown Facility
Xi'an, Shaanxi, 710032, China
Unknown Facility
Xi'an, Shaanxi, 710038, China
Unknown Facility
Xi'an, Shaanxi, 710061, China
Unknown Facility
Chengdu, Sichuan, 610041, China
Unknown Facility
Beijing, 100039, China
Unknown Facility
Beijing, 100069, China
Unknown Facility
Beijing, 100071, China
Unknown Facility
Beijing, 100142, China
Unknown Facility
Chongqing, 400038, China
Unknown Facility
Shanghai, 200001, China
Unknown Facility
Shanghai, 200032, China
Unknown Facility
Shanghai, 201805, China
Unknown Facility
Tianjin, 300060, China
Unknown Facility
Hradec Králové, 500 05, Czechia
Unknown Facility
Olomouc, 775 20, Czechia
Unknown Facility
Prague, 128 08, Czechia
Unknown Facility
Angers, 49100, France
Unknown Facility
Caen, F-14033, France
Unknown Facility
Clichy, 92110, France
Unknown Facility
Créteil, 94010, France
Unknown Facility
Dijon, 21000, France
Unknown Facility
La Tronche, 38700, France
Unknown Facility
Lille, 59037, France
Unknown Facility
Lyon, 69004, France
Unknown Facility
Marseille, 13005, France
Unknown Facility
Montpellier, 34295, France
Unknown Facility
Nice, 06202, France
Unknown Facility
Paris, 75020, France
Unknown Facility
Paris, 75651, France
Unknown Facility
Perpignan, 66000, France
Unknown Facility
Reims, 51092, France
Unknown Facility
Rennes, 35062, France
Unknown Facility
Toulouse, 31059, France
Unknown Facility
Vandœuvre-lès-Nancy, 54500, France
Unknown Facility
Villejuif, 94805, France
Unknown Facility
Heidelberg, Baden-Wurttemberg, 69120, Germany
Unknown Facility
München, Bavaria, 81377, Germany
Unknown Facility
Frankfurt am Main, Hesse, 60590, Germany
Unknown Facility
Hanover, Lower Saxony, 30625, Germany
Unknown Facility
Aachen, North Rhine-Westphalia, 52074, Germany
Unknown Facility
Cologne, North Rhine-Westphalia, 50937, Germany
Unknown Facility
Essen, North Rhine-Westphalia, 45136, Germany
Unknown Facility
Mainz, Rhineland-Palatinate, 55131, Germany
Unknown Facility
Magdeburg, Saxony-Anhalt, 39120, Germany
Unknown Facility
Berlin, 13353, Germany
Unknown Facility
Hamburg, 20246, Germany
Unknown Facility
Budapest, 1097, Hungary
Unknown Facility
Debrecen, 4032, Hungary
Unknown Facility
Kaposvár, 7400, Hungary
Unknown Facility
Foggia, Apulia, 71013, Italy
Unknown Facility
Napoli, Campania, 80131, Italy
Unknown Facility
Bologna, Emilia-Romagna, 40138, Italy
Unknown Facility
Modena, Emilia-Romagna, 41124, Italy
Unknown Facility
Rome, Lazio, 00168, Italy
Unknown Facility
Genoa, Liguria, 16132, Italy
Unknown Facility
Bergamo, Lombardy, 24127, Italy
Unknown Facility
Milan, Lombardy, 20089, Italy
Unknown Facility
Milan, Lombardy, 20122, Italy
Unknown Facility
Novara, Piedmont, 28100, Italy
Unknown Facility
Turin, Piedmont, 10126, Italy
Unknown Facility
Cagliari, Sardinia, 09134, Italy
Unknown Facility
Pisa, Tuscany, 56126, Italy
Unknown Facility
Padua, Veneto, 35128, Italy
Unknown Facility
Chiba, Chiba, 260-8677, Japan
Unknown Facility
Kashiwa-shi, Chiba, 277-8577, Japan
Unknown Facility
Fukuoka, Fukuoka, 810-8563, Japan
Unknown Facility
Iizuka-shi, Fukuoka, 820-8505, Japan
Unknown Facility
Yokohama, Kanagawa, 232-0024, Japan
Unknown Facility
Kumamoto, Kumamoto, 860-8556, Japan
Unknown Facility
Osaka, Osaka, 541-8567, Japan
Unknown Facility
Osakasayama-shi, Osaka, 589-8511, Japan
Unknown Facility
Utsunomiya, Tochigi, 321-0974, Japan
Unknown Facility
Chiyoda-ku, Tokyo, 101-0062, Japan
Unknown Facility
Chuo-ku, Tokyo, 104-0045, Japan
Unknown Facility
Musashino-shi, Tokyo, 180-8610, Japan
Unknown Facility
Amsterdam, 1105 AZ, Netherlands
Unknown Facility
Leiden, 2333 ZA, Netherlands
Unknown Facility
Barnaul, 656045, Russia
Unknown Facility
Moscow, 119991, Russia
Unknown Facility
Moscow, Russia
Unknown Facility
Singapore, 119228, Singapore
Unknown Facility
Busan, Busan Gwang''yeogsi, 49241, South Korea
Unknown Facility
Daegu, 700-721, South Korea
Unknown Facility
Seoul, 06351, South Korea
Unknown Facility
Seoul, 110-744, South Korea
Unknown Facility
Oviedo, Principality of Asturias, 33011, Spain
Unknown Facility
Alicante, 03010, Spain
Unknown Facility
Barcelona, 08035, Spain
Unknown Facility
Barcelona, 08036, Spain
Unknown Facility
Córdoba, 14004, Spain
Unknown Facility
Madrid, 28007, Spain
Unknown Facility
Madrid, 28041, Spain
Unknown Facility
Madrid, 28050, Spain
Unknown Facility
Zaragoza, 50009, Spain
Unknown Facility
Bellinzona, Canton Ticino, 6500, Switzerland
Unknown Facility
Bern, 3010, Switzerland
Unknown Facility
Kaohsiung City, Kaohsiung, 83301, Taiwan
Unknown Facility
Taipei, 10016, Taiwan
Unknown Facility
Taipei, 11217, Taiwan
Unknown Facility
Taoyuan District, 333, Taiwan
Unknown Facility
Birmingham, West Midlands, B15 2WB, United Kingdom
Unknown Facility
Leeds, West Yorkshire, LS9 7TF, United Kingdom
Unknown Facility
Bristol, BS2 8ED, United Kingdom
Unknown Facility
London, SE5 9RS, United Kingdom
Unknown Facility
London, W12 0HS, United Kingdom
Related Publications (4)
Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26.
PMID: 29704513RESULTBruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6.
PMID: 27932229RESULTWu W, Mao H, Song J, Yang F. Bibliometric analysis of hepatocellular carcinoma and tyrosine kinase inhibitors. Medicine (Baltimore). 2025 May 16;104(20):e42015. doi: 10.1097/MD.0000000000042015.
PMID: 40388796DERIVEDTeufel M, Seidel H, Kochert K, Meinhardt G, Finn RS, Llovet JM, Bruix J. Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma. Gastroenterology. 2019 May;156(6):1731-1741. doi: 10.1053/j.gastro.2019.01.261. Epub 2019 Feb 6.
PMID: 30738047DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Limitations and Caveats
Decimal places were automatically truncated if last decimal equals zero.
Results Point of Contact
- Title
- Therapeutic Area Head
- Organization
- Bayer AG
Study Officials
- STUDY DIRECTOR
Bayer Study Director
Bayer
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- LTE60
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 21, 2013
First Posted
January 24, 2013
Study Start
May 14, 2013
Primary Completion
February 29, 2016
Study Completion
July 5, 2019
Last Updated
August 20, 2020
Results First Posted
June 5, 2017
Record last verified: 2020-08